Q2 2025 Theravance Biopharma Inc Earnings Call Transcript

Aug 12, 2025 / 09:00 PM GMT

Release Date Price: $11.92 (+4.56%)

Transcript 10-Q8-K

Key Points

Positve

Theravance Biopharma Inc (TBPH) reported a strong quarter with net sales reaching approximately $66 million, driven by demand growth and favorable pricing.
The company completed a $225 million sale of its remaining royalty interests in Trilogy to GSK, significantly strengthening its balance sheet.
The phase 3 Cypress trial for amproloxetine is progressing well, with enrollment nearing completion and top-line data expected in six months.
Theravance Biopharma Inc (TBPH) ended the quarter with approximately $340 million in cash and no debt, maintaining a strong financial position.
The company is on track to achieve significant milestones, including a potential $150 million from royalty Pharma over the next 18 months.

Negative

The company did not provide guidance on the formal launch timing for Upellry in China, as Beatrice is still finalizing the commercialization plan.
There is uncertainty regarding the pricing strategy for amproloxetine, as it is still early to determine a specific price point.
The company faces challenges in ensuring proper education for clinicians to make the best decisions for patient needs, particularly in specialty pharmacy channels.
Theravance Biopharma Inc (TBPH) expects to pay approximately $27 million in taxes related to the Trilogy royalty sale in the second half of the year.
There is potential for pushback on amproloxetine pricing and reimbursement, given the presence of generics with less efficacy and clear side effects.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TBPH.OQ - Theravance Biopharma Inc
Q2 2025 Theravance Biopharma Inc Earnings Call
Aug 12, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good afternoon. I'd like to welcome everyone to the fairvan Biopharma 2nd quarter 2025 conference call.

During the presentation, all participants will be in a listen-only mode. The question and answer session will follow the company's formal remarks. To ask a question, press 11 on your telephone. If listening via webcast, please mute audio on your webcast device before asking a question over the phone. I will repeat these instructions after management completes their prepared remarks. Also, today's conference is being recorded.

And now I would like to turn the call over to Rick Winningham, Chief Executive Officer. Please go ahead, sir.

------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.